Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Ginkgo Bioworks Holdings, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SAN FRANCISCO--(BUSINESS WIRE)--THERMO FISHER SCIENTIFIC, THE WORLD LEADER IN SERVING SCIENCE, TODAY ANNOUNCED THAT THE APPLIED BIOSYSTEMS RAPIDINTEL PLUS CARTRIDGE HAS RECEIVED APPROVAL FROM THE FEDERAL BUREAU OF INVESTIGATION (FBI) NATIONAL DNA INDEX SYSTEM (NDIS) FOR USE WITH QUALIFYING FORENSIC CRIME SCENE SAMPLES. THE LAW ENFORCEMENT MILESTONE MAKES THERMO FISHER'S RAPID DNA WORKFLOW ON THE RAPIDHIT ID SYSTEM THE FIRST ELIGIBLE TO GENERATE DNA PROFILES THAT CAN BE SEARCHED AGAINST THE N.

THERMO FISHER SCIENTIFIC RECEIVES FIRST FBI APPROVAL FOR RAPID DNA CRIME SCENE PROFILES ELIGIBLE FOR NATIONAL CODIS SEARCHES

TAIPEI, TAIWAN, JULY 02, 2026 (GLOBE NEWSWIRE) -- YD BIO LIMITED (YD BIO OR THE COMPANY) (NASDAQ: YDES), A BIOTECHNOLOGY COMPANY ADVANCING DNA METHYLATIONBASED CANCER DETECTION TECHNOLOGY AND OPHTHALMOLOGIC INNOVATIONS, TODAY ANNOUNCED THAT ITS AFFILIATE, EG BIOMED US INC., A DELAWARE CORPORATION (EG BIOMED US), HAS OBTAINED OUT-OF-STATE CLINICAL LABORATORY LICENSES IN RHODE ISLAND AND PENNSYLVANIA FOR ITS CLIA-CERTIFIED, CAP-ACCREDITED LABORATORY IN BOTHELL, WASHINGTON (CLIA #50D2316600), REINFORCING THE COMPANY'S TRANSITION FROM A COLLECTION OF TECHNOLOGIES TO A PLATFORM-BASED BIOTECHNOLOGY COMPANY ANCHORED IN CLINICALLY DERIVED MOLECULAR DATA.

YD BIO EXPANDS U.S. LABORATORY FOOTPRINT TO 46 STATES, STRENGTHENING DNA-METHYLATION EARLY CANCER DETECTION OPERATIONS

BOULDER, COLO.--(BUSINESS WIRE)-- #ARCHERANALYSIS--IDT'S LIBRARY PREP SOLUTIONS JOIN ILLUMINA'S EXTENSIVE SOFTWARE ECOSYSTEM TO ENABLE STREAMLINED ANALYSIS FOR IDT'S FFPE AND CFDNA WORKFLOWS.

INTEGRATED DNA TECHNOLOGIES ANNOUNCES END-TO-END ONCOLOGY RESEARCH WORKFLOWS OPTIMIZED ON ILLUMINA SOFTWARE FOR FASTER INSIGHTS

CHICAGO--(BUSINESS WIRE)--TEMPUS AI, INC. (NASDAQ: TEM), A TECHNOLOGY COMPANY LEADING THE ADOPTION OF AI TO ADVANCE PRECISION MEDICINE, TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS GRANTED APPROVAL FOR A TUMOR-ONLY INDICATION FOR ITS XT CDX NEXT-GENERATION SEQUENCING PLATFORM. WITH THIS EXPANDED LABEL, TEMPUS IS THE FIRST LABORATORY TO HOLD FDA COMPANION DIAGNOSTIC (CDX) APPROVAL FOR BOTH TUMOR-ONLY AND TUMOR-NORMAL COMPREHENSIVE GENOMIC PROFILING. TEMPUS XT CDX IS A 648.

TEMPUS RECEIVES FDA APPROVAL FOR TUMOR ONLY XT CDX, ENABLING MIGRATION OF ITS ENTIRE DNA SOLID TUMOR PORTFOLIO

NEW CO-DEVELOPED PRODUCT DELIVERS A COMPLETE TIER 1 ADME PANEL COUPLED WITH BEST-IN-CLASS AI-DRIVEN HUMAN PHARMACOKINETIC (PK) PROJECTION AND INTEGRATED COMPOUND MANAGEMENT ENABLING SCIENTISTS TO MAKE LEAD-OPTIMIZATION-QUALITY DECISIONS STARTING IN HIT IDENTIFICATION BOSTON, MAY 26, 2026 /PRNEWSWIRE/ -- GINKGO BIOWORKS(NYSE: DNA) TODAY ANNOUNCED THAT ITS DATAPOINTS OFFERING IS LAUNCHING ADME-ONE , A FULLY INTEGRATED ADME PLATFORM FOR DRUG DISCOVERY TEAMS CO-DEVELOPED WITH TANGIBLE SCIENTIFIC AND INDUCTIVE BIO . ADME-ONE DELIVERS A HIGH-THROUGHPUT TIER 1 ADME (ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION) PANEL PAIRED WITH BEST-IN-CLASS AI-POWERED HUMAN PHARMACOKINETIC (PK) PROJECTION AND FULLY INTEGRATED COMPOUND MANAGEMENT.

GINKGO DATAPOINTS, TANGIBLE SCIENTIFIC, AND INDUCTIVE BIO LAUNCH ADME-ONE: A HIGH-THROUGHPUT ADME PLATFORM THAT BRINGS PHARMACOKINETIC PROJECTION EARLIER IN DRUG DISCOVERY

RESULTS PROVIDE IMPORTANT CLINICAL EVIDENCE TO SUPPORT APOLLOBIO'S FUTURE REGULATORY SUBMISSION IN CHINA OF VGX-3100, INOVIO'S DNA IMMUNOTHERAPY CANDIDATE APOLLOBIO'S NEW CLINICAL RESULTS FURTHER HIGHLIGHT THE POTENTIAL OF INOVIO'S DNA MEDICINE PLATFORM TO TREAT DISEASES CAUSED BY INFECTION WITH VARIOUS STRAINS OF THE HUMAN PAPILLOMAVIRUS (HPV), ELIMINATING OR REDUCING THE NEED FOR SURGICAL INTERVENTIONS PLYMOUTH MEETING, PA., MAY 21, 2026 /PRNEWSWIRE/ -- INOVIO (NASDAQ: INO), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING DNA MEDICINES TO HELP TREAT AND PROTECT PEOPLE FROM HPV-RELATED DISEASES, CANCER, AND INFECTIOUS DISEASES, TODAY ANNOUNCED THAT ITS PARTNER FOR VGX-3100 IN CHINA, APOLLOBIO, ANNOUNCED POSITIVE TOPLINE RESULTS FROM ITS PIVOTAL PHASE 3 TRIAL OF VGX-3100, INOVIO'S INVESTIGATIONAL DNA IMMUNOTHERAPY BEING DEVELOPED AS A POTENTIAL TREATMENT FOR CERVICAL DYSPLASIA.

POSITIVE TOPLINE RESULTS FROM A PHASE 3 TRIAL FOR VGX-3100 IN CERVICAL DYSPLASIA PATIENTS ANNOUNCED BY APOLLOBIO, INOVIO'S PARTNER IN CHINA

CLOSED SALE OF THE COMPANY'S MOBILE DEVICE ASSETS TO NEXA IN JANUARY 2026 COMPLETED THE TRANSFER OF THE OPERATIONS OF THE PHONE AND HOTSPOT BUSINESS TO NEXA FOCUSED ON ENHANCING THE DNA X TRADING PLATFORM TO PREPARE THE PLATFORM FOR ITS INITIAL GROWTH PHASE SAN DIEGO, CALIFORNIA--(NEWSFILE CORP. - MAY 20, 2026) - DNA X, INC. (NASDAQ: SONM), A PROVIDER OF CRYPTOCURRENCY TRADING SERVICES, TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026. THE COMPANY OPERATES THE DNA X AI TRADING PLATFORM BUSINESS, AND EXPECTS TO LAUNCH AN ENHANCED VERSION TO THE PUBLIC LATER THIS YEAR.

DNA X, INC. REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

HARMONIC'S SEASTAR OPTICAL NODE ENABLES COST-EFFECTIVE BROADBAND SERVICE EXPANSION IN PREVIOUSLY UNDERSERVED BROWNFIELD MDU ENVIRONMENTS SAN JOSE, CALIF., MAY 19, 2026 /PRNEWSWIRE/ -- HARMONIC (NASDAQ: HLIT) TODAY ANNOUNCED THAT DNA FINLAND, THE SECOND LARGEST MOBILE AND FIXED BROADBAND OPERATOR SERVING THE FINNISH MARKET, IS EXPANDING MULTI-GIGABIT SERVICES INTO LOWER-DENSITY MULTI-DWELLING UNITS (MDUS) WITH HARMONIC'S SEASTAR OPTICAL NODE.

DNA FINLAND EXTENDS FIBER-GRADE CONNECTIVITY TO LOWER-DENSITY MDUS WITH HARMONIC

NEW YORK, MAY 11, 2026 (GLOBE NEWSWIRE) -- LOTUS TECHNOLOGY INC. (LOTUS TECH OR THE COMPANY) (NASDAQ: LOT), A LEADING GLOBAL INTELLIGENT AND LUXURY MOBILITY PROVIDER, TODAY ANNOUNCED FOCUS 2030 FOR LOTUS, AN EVOLVED BUSINESS STRATEGY DESIGNED TO UNDERPIN ITS COMPETITIVENESS AND TRANSFORMATION INTO A MORE FLEXIBLE AND SUSTAINABLE BUSINESS MODEL ENSURING MARKET RESILIENCE AMID EXTERNAL HEADWINDS.

LOTUS UNVEILS FOCUS 2030  REINFORCING BRAND DNA WITH AN ALL-NEW HYBRID-V8 SUPERCAR

GINKGO PROVIDES AN UPDATE ON ITS FIRST QUARTER FINANCIAL RESULTS FOLLOWING THE DIVESTITURE OF ITSBIOSECURITY BUSINESS BOSTON, MAY 7, 2026 /PRNEWSWIRE/ -- GINKGOBIOWORKS HOLDINGS, INC. (NYSE: DNA, "GINKGO") TODAY ANNOUNCED ITS RESULTS FOR THE FIRST QUARTER OF 2026 THAT ENDED MARCH 31, 2026. THE UPDATE, INCLUDING A WEBCAST SLIDE PRESENTATION WITH ADDITIONAL DETAILS ON THE FIRST QUARTER, AS WELL AS SUPPLEMENTAL FINANCIAL INFORMATION, WILL BE AVAILABLE AT INVESTORS.GINKGOBIOWORKS.COM.

Ginkgo Bioworks Holdings, Inc.

DNA

Price

Financial Reports

No items found.

Press Releases

Ginkgo Bioworks Holdings, Inc.

DNA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

DNA